



Realizing the Ardelyx Mission, One Novel Therapy at a Time

Ardelyx's performance in 2022 captures the results of well over a decade of hard work, dedication and tenacity on the part of the entire Ardelyx team, and countless supporters in the patient and physician communities. Through challenges and uncertainties, the team at Ardelyx has demonstrated its profound commitment to doing the necessary work to bring novel mechanism products to patients in need. As a result, we are closer to realizing the vision of Ardelyx: A healthier tomorrow for patients with significant unmet medical needs.

As an evolving, commercial biotechnology company, we had the privilege of bringing a meaningful new treatment option to patients in March of 2022 when we launched IBSRELA for adult patients suffering from irritable bowel syndrome with constipation. Many of these patients are in need of a novel treatment, and the consistent and significant quarter-over-quarter growth we reported confirms to us that patients are accessing the drug and responding favorably to treatment.

Now, we have the opportunity to deliver on our mission a second time with the launch of XPHOZAH later this year, pending FDA approval. The support and tireless efforts of the patient and physician communities strengthened our own team's commitment to seeing this much needed treatment continue on its path to patients. We now stand ready to resubmit the NDA for XPHOZAH following the successful Cardiovascular and Renal Drugs Advisory Committee meeting and the granting of our appeal by the FDA's Office of New Drugs.

The future for Ardelyx will be built upon the success earned over the past 12-months. The values of our organization, passionate, dedicated, fearless and inclusive, will continue to serve as our foundation as we seek to continue the growth momentum for IBSRELA, successfully launch and bring XPHOZAH to patients if approved, and envision the next phase of Ardelyx: creating more opportunities to discover, develop and commercialize innovative, best-in-class medicines that meet significant unmet medical needs.

Mike Raab
President and CEO, Ardelyx